1. Ketamine for the treatment of Refractory Status Epilepticus 2. Heterogeneity of Leucine-Rich Repeat Kinase 2 Mutations: Genetics, Mechanisms, and Therapeutic Implications 3. Glioblastoma: Treatment Challenges and Future Directions."

Neurology/Neurosurgery Grand Rounds

Friday June 7, 2019 at 8:00 AM


This grand round has already taken place.


HSC level 3, lecture hall 6 - Stony Brook, NY
June 7th, 2019
1.00 AMA PRA Category 1 Credit Hours

Description

A variety of discussions on Neurology case studies. 

Dates and Times

Start: 6/7/2019 8:00 AM
End: 6/7/2019 9:00 AM

Objectives

1) The basics for early rational polypharmacotherapy and
neuroprotective strategies in Status Epilepticus. 2) Intravenous
Ketamine Infusion: Challenges and Opportunities.3) Current guidelines
to use IV Ketamine for Refractory Status Epilepticus at Stony Brook
Hospital: the QA Project.

2) Mutations in LRRK2 is the most
common genetic cause of Parkison's disease. 2.0Mechanisms of these
mutations are heterogeneous which implicate diverse therapeutic
approaches for patients with different LRRK2 mutations.

3) 1. Understanding the current state of GBM therapies. 2. Understanding treatment challenges and resistance.3.Understanding new and potential therapies currently being investigated

4) Title- Heterogeneity of Leucine-Rich Repeat Kinase 2 Mutations: Genetics, Mechanisms, and Therapeutic Implications. Mutations in LRRK2 is the most common genetic cause of Parkison's disease. Mechanisms of these mutations are heterogeneous which implicate diverse therapeutic approaches for patients with different LRRK2 mutations.

5)Title-Fetal Surgery for Spina Bifida. Understand differences in outcomes between patients who have received fetal vs postnatal surgery for closure of myelomeningocele. Understand potential complications & risks of fetal surgery for myelomeningocele

6)Title- When is it safe to start Anti-coagulation after an Acute Ischemic Stroke? This talk will cover current literature looking at when is it considered safe to start AC and then review data from Stony Brook. The talk will end with an overview of current multi-center clinical trials that are currently enrolling patients in order to answer this question.

Speakers

  • Dr. Emilio Garrido
    • Ketamine for the treatment of Refractory Status Epilepticus
  • Dr. Alexander Ou
    • Glioblastoma: Treatment Challenges and Future Directions
  • Dr. Shannon Pollock
    • Fetal Surgery for Spina Bifida
  • Dr. Lakov Rudenko
    • Heterogeneity of Leucine-Rich Repeat Kinase 2 Mutations: Genetics, Mechanisms, and Therapeutic Implications
  • Dr. Usman Shehzad
    • When is it safe to start Anti-coagulation after an Acute Ischemic Stroke
  • Dr. Kamil Stefanowski
    • Early Impairment of Consciousness in Ischemic Stroke

Location

HSC level 3, lecture hall 6
Stony Brook Medicine
Stony Brook, NY 11794

Accreditation

The School of Medicine, State University of New York at Stony Brook, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The School of Medicine, State University of New York at Stony Brook designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s) . Physicians should only claim the credit commensurate with the extent of their participation in the activity.

Give us a call
(631) 444-2094
Office of Continuing Medical Education
Renaissance School of Medicine at Stony Brook University
HSC, Level 2, Room 142
Stony Brook, New York 11794-8222